Venetoclax Registry
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax
Acute Myeloid Leukemia
DRUG: Venetoclax
Overall response rate of Venetoclax treatment., Overall response rate of Venetoclax treatment (complete remission, complete remission with incomplete regeneration, partial remission), 4 months
Event-free survival during Venetoclax treatment, Event-free survival of patients with relapsed/refractory AML receiving Venetoclax, 5 years|Relapse-free survival during Venetoclax treatment, Relapse-free survival of patients with relapsed/refractory AML receiving Venetoclax, 5 years|Overall survival during Venetoclax treatment, Overall survival of patients with relapsed/refractory AML receiving Venetoclax, 5 years
The aim of this study is to document all patients with AML who are treated with the BCL2 inhibitor Venetoclax outside a clinical trial in all hospitals participating in this registry study in a standardised manner. Data is collected retrospectively and multi-centric. It is neither a therapy study nor is the therapy influenced by this study.

1. Systematic and uniform collection and documentation of all patients treated with the BCL2 inhibitor Venetoclax.
2. Collection and integrative analysis of clinical data of included patients.
3. Mutation analysis of available patient samples and correlation with clinical parameters.